Qi Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qi Guo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Guoqi Shi
Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China
1 shared publication - Jie Li
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
1 shared publication - Jingya Wang
Guiyang Kangyang University, China
1 shared publication - Lin Yao
Institute of Acupuncture and Moxibustion Shandong University of Traditional Chinese Medicine Jinan China
1 shared publication Ruth B. Caldwell
Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA
1 shared publication- Shengxuan Sun
South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Protection against Doxorubicin‐Induced Cardiotoxicity through Modulating iNOS/ARG 2 Balance by Electroacupuncture at PC6
Background. Doxorubicin (DOX) is a commonly used chemotherapeutic drug but is limited in clinical applications by its cardiotoxicity. Neiguan acupoint (PC6) is a well‐recognized acupoint for the treatment of cardiothoracic disease. However, whether acupuncture at PC6 could be effective in preventing DOX‐induced cardiotoxicity is still unknown. Methods. A set of experiments were performed with myocardial cells, wild type, inducible nitric oxide synthase knockout (iNOS‐/‐), and myocardial‐specific ablation arginase 2 (Myh6‐ARG 2‐/‐) mice. We investigated the protective effect and the underlying mechanisms for electroacupuncture (EA) against DOX‐induced cardiotoxicity by echocardiography, immunostaining, biochemical analysis, and molecular biotechnology in vivo and in vitro analysis. Results. We found that DOX‐mediated nitric oxide (NO) production was positively correlated with the iNOS level but has a negative correlation with the arginase 2 (ARG 2) level in both myocardial cells and tissues. Meanwhile, EA at PC6 alleviated cardiac dysfunction and cardiac hypertrophy in DOX‐treated mice. EA at PC6 blocked the upregulation of NO production in accompanied with the downregulated iNOS and upregulated ARG 2 levels in myocardial tissue induced by DOX. Furthermore, knockout iNOS prevented cardiotoxicity and EA treatment did not cause the further improvement of cardiac function in iNOS‐/‐ mice treated by DOX. In contrast, deficiency of myocardial ARG 2 aggravated DOX‐induced cardiotoxicity and reduced EA protective effect. Conclusion. These results suggest that EA treatment at PC6 can prevent DOX‐induced cardiotoxicity through modulating NO production by modulating the iNOS/ARG 2 balance in myocardial cells.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessProtection against Doxorubicin‐Induced Cardiotoxicity through Modulating iNOS/ARG 2 Balance by Electroacupuncture at PC6
Background. Doxorubicin (DOX) is a commonly used chemotherapeutic drug but is limited in clinical applications by its cardiotoxicity. Neiguan acupoint (PC6) is a well‐recognized acupoint for the treatment of cardiothoracic disease. However, whether acupuncture at PC6 could be effective in preventing DOX‐induced cardiotoxicity is still unknown. Methods. A set of experiments were performed with myocardial cells, wild type, inducible nitric oxide synthase knockout (iNOS‐/‐), and myocardial‐specific ablation arginase 2 (Myh6‐ARG 2‐/‐) mice. We investigated the protective effect and the underlying mechanisms for electroacupuncture (EA) against DOX‐induced cardiotoxicity by echocardiography, immunostaining, biochemical analysis, and molecular biotechnology in vivo and in vitro analysis. Results. We found that DOX‐mediated nitric oxide (NO) production was positively correlated with the iNOS level but has a negative correlation with the arginase 2 (ARG 2) level in both myocardial cells and tissues. Meanwhile, EA at PC6 alleviated cardiac dysfunction and cardiac hypertrophy in DOX‐treated mice. EA at PC6 blocked the upregulation of NO production in accompanied with the downregulated iNOS and upregulated ARG 2 levels in myocardial tissue induced by DOX. Furthermore, knockout iNOS prevented cardiotoxicity and EA treatment did not cause the further improvement of cardiac function in iNOS‐/‐ mice treated by DOX. In contrast, deficiency of myocardial ARG 2 aggravated DOX‐induced cardiotoxicity and reduced EA protective effect. Conclusion. These results suggest that EA treatment at PC6 can prevent DOX‐induced cardiotoxicity through modulating NO production by modulating the iNOS/ARG 2 balance in myocardial cells.